IN THE CLAIMS

Please amend the claims as follows:

1. (previously presented) Process for the preparation of Flecainide, as Flecainide base or any pharmaceutically acceptable salts thereof, comprising:

preparation of a compound of formula VI

wherein R1 is H, alkali metal or a C1 to C9 alkyl group;

from compounds of formula III

wherein X¹ is F, Cl, Br or I;

optional conversion of the compound of formula VI to the ester of formula VII by reacting with a hydroxyl compound R²OH;

wherein R2 is C1 to C9 alkyl group, aryl group or succinimidyl;

amide formation of the compound of formula VI or VII forming flecainide base by reacting with 2-(aminomethyl)piperidine and;

optionally forming a pharmaceutically acceptable salt thereof.

- 2. (original) The process of Claim 1 wherein the amide formation is selective.
- 3. (cancelled)
- 4. (previously presented) Process for the preparation of Flecainide, as Flecainide base or any pharmaceutically acceptable salts thereof, comprising

reaction of the 2-halobenzoic acid derivatives of formula III with an alkali or alkaline earth metal alkoxide of 2,2,2-trifluoroethanol in the presence of a copper-containing catalyst in a solvent to form 2-(2,2,2-trifluoroethoxy)benzoic acid derivatives of formula IV;

$$X^1$$
 $COOR^1$ $COOR^1$ (IV)

wherein X1 is F, Cl, Br or I and R1 is H, alkali metal or a C1 to C9 alkyl group;

halogenation of the compounds of formula IV to form 5-halo-2-(2,2,2-trifluoroethoxy)benzoic acid derivatives of formula V;

wherein X² is Cl, Br, or I.

reaction of the compounds of formula V with an alkali or alkaline earth metal alkoxide of 2,2,2-trifluoroethanol in the presence of a copper-containing catalyst in a solvent to form compounds of formula VI;

wherein R1 is H, alkali metal or a C1 to C9 alkyl group;

optional conversion of the compounds of formula VI to a new ester of formula VII by reacting with hydroxyl compound R²OH;

wherein R² is C₁ to C₉ alkyl group, aryl group or succinimidyl;

selective amide formation by reacting compounds of formula VI or VII with 2-(aminomethyl)piperidine forming flecainide base;

optionally forming a pharmaceutically acceptable salt thereof.

- 5. (original) The process of Claim 4 wherein either solvent comprises a polar solvent.
- 6. (original) The process of Claim 4 wherein the pharmaceutically acceptable salt is the monoacetate salt.
- 7. (original) The process according to Claim 4, wherein the alkali or alkaline earth metal alkoxide of 2,2,2-trifluoroethoxide is sodium, potassium, calcium or lithium 2,2,2-trifluoroethoxide.
- 8. (previously presented) The process according to Claim 4, wherein the alkali or alkaline earth metal alkoxide of 2,2,2-trifluoroethanol is synthesized by reacting 2,2,2-trifluoroethanol with a base selected from potassium *tert*-butoxide, sodium *tert*-butoxide, sodium isopropoxide and sodium methoxide.

9. (cancelled)

- 10. (previously presented) The process according to Claim 4 wherein the copper-containing catalyst comprises cupric chloride, cupric bromide, cupric iodide, cuprous chloride, cuprous bromide, cuprous iodide, copper (I) oxide, copper (II) oxide or copper-zinc alloy.
- 11. (original) The process according to Claim 4, wherein X^2 is Br.
- 12. (original) The process according to Claim 4, wherein R² is selected from methyl, ethyl, benzyl and phenyl.
- 13. (original) The process according to Claim 4, wherein the compound of formula VI or VII is 2,5-bis-(2,2,2-trifluoroethoxy)benzoate.
- 14.(original) The process according to Claim 13 wherein any of the reactions is carried out in aliphatic, cycloaliphatic or aromatic solvents from 5 to 10 carbon atoms or ethers from 4 to 10 carbon atoms.

15. (previously presented) The process according to Claim 14, wherein the solvents comprise hexane, heptane, cyclohexane, tetrahydrofuran, 1,2-domethoxyethane, diethyleneglycol dimethyl ether, toluene, xylene, or acetonitrile.

16. (original) The process according to Claim 13, wherein the reaction temperature is between 0°C to 150°C.

17. (original) The process according to Claim 13, wherein the temperature is between 50°C to 120°C.

18. (original) The process according to Claim 13, wherein the molar ratio between 2,5-bis-(2,2,2-trifluoroethoxy)benzoate and 2-aminomethylpiperidine is from 1:1 to 1:2.

19. (original) The process according to Claim 18, wherein the molar ratio is from 1:1 to 1:1.5.

20 (previously presented) The process for the preparation benzoic acid derivatives of formula VI;

wherein R¹ is H, alkali metal or a C₁ to C₉ alkyl group;

from compounds of formula III

wherein X1 is F, Cl, Br or I;

comprising:

reaction of compounds of formula III with an alkali or alkaline earth metal alkoxide of 2,2,2-trifluoroethanol in the presence of a copper-containing catalyst in a solvent to form compounds of formula IV;

wherein R1 is H, alkali metal or a C1 to C9 alkyl group;

halogenation of the compounds of formula IV to form compounds of formula V;

wherein X2 is Cl, Br, or I[[.]];

reaction of compounds of formula V with an alkali or alkaline earth metal alkoxide of 2,2,2-trifluoroethanol in the presence of a copper-containing catalyst in a solvent.

- 21. (original) The process according to Claim 20 wherein either solvent comprises a polar solvent.
- 22. (original) The process according to Claim 20, wherein the alkali or alkaline earth metal alkoxide of 2,2,2-trifluoroethoxide is sodium, potassium, calcium or lithium 2,2,2-trifluoroethoxide.
- 23. (previously presented) The process according to Claim 20, wherein the alkali or alkaline earth metal alkoxide of 2,2,2-trifluoroethoxide is synthesized by reacting 2,2,2-trifluoroethanol with a base

selected from potassium *tert*-butoxide, sodium *tert*-butoxide, sodium isopropoxide <u>and</u> or sodium methoxide.

24. (cancelled)

- 25. (previously presented) The process according to Claim 20 wherein the copper-containing catalyst comprises cupric chloride, cupric bromide, cupric iodide, cuprous chloride, cuprous bromide, cuprous iodide, copper (I) oxide, copper (II) oxide, or copper-zinc alloy.
- 26. (original) The process according to Claim 20, wherein X² is Br.
- 27. (currently amended) The process for the preparation of Flecainide from 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid derivatives of formula VII,

wherein R² is C₁ to C₂ alkyl group, aryl group or succinimidyl and wherein R² is not 2,2,2-trifluoroethyl or cynomethyl groups methyl, ethyl, propyl, butyl, benzyl, phenyl or succinimidyl;

comprising the selective amide formation by reacting the benzoic acid derivative of formula VII with 2-(aminomethyl)piperidine.

- 28. (original) The process according to Claim 27, wherein the reaction is carried out in aliphatic, cycloaliphatic or aromatic solvents from 5 to 10 carbon atoms or ethers from 4 to 10 carbon atoms.
- 29.(currently amended) The process according to Claim 28 27, wherein the <u>reaction is carried out in solvents and the</u> solvents are selected from hexane, heptane, cyclohexane, tetrahydrofuran, 1,2-demethoxyethane, diethyleneglycol dimethyl ether, toluene, xylene, acetonitrile.

- 30. (previously presented) The process according to Claim 28, wherein the solvent is toluene or xylene.
- 31. (original) The process according to Claim 27, wherein the reaction temperature is between 0°C and 150°C.
- 32. (original) The process according to Claim 27, wherein temperature range is between 50°C and 120°C.
- 33. (original) The process according to Claim 27, wherein the molar ratio between the benzoic acid derivative and 2-aminomethylpiperidine is from 1:1 to 1:2.
- 34. (original). The process according to Claim 33, wherein the molar ratio is from 1:1 to 1:1.5.
- 35. (original) 5-Bromo-2-(2,2,2-trifluoroethoxy)benzoic acid.